Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease.
about
DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in miceUse of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cellsControl of STDs--the role of prophylactic vaccines against herpes simplex virus.Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.The murine intravaginal HSV-2 challenge model for investigation of DNA vaccines.Prospects for control of herpes simplex virus disease through immunization.Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.Activation of skin dendritic cells by immunostimulatory DNA.DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vectorCellular HIV-1 immune responses in natural infection and after genetic immunization.Boosting immune response to hepatitis B DNA vaccine by coadministration of Prothymosin alpha-expressing plasmid.Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.Prospects and perspectives for development of a vaccine against herpes simplex virus infections.Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections.Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.DNA vaccines for the prophylaxis and modulation of HSV infections.Glycoprotein D adjuvant herpes simplex virus vaccine.Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virusVaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infectionNegative-strand RNA viruses: genetic engineering and applications.The ongoing pursuit of a prophylactic HSV vaccine.Progress in the development of DNA vaccines against foot-and-mouth disease.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection.Control of immune responses by gene immunization.DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors.Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.Protection against herpes B virus infection in rabbits with a recombinant vaccinia virus expressing glycoprotein D.
P2860
Q27469515-07ED65AB-636C-4D28-8672-500A867C178DQ33201424-23A9E4D8-53CE-40A6-BFCE-BFBB6042BE97Q33589337-6580425C-9C25-4EC1-8761-BEB88272DFB5Q33645053-35A9C5DE-9E5C-458D-AB51-57FCDA4C72B8Q33785966-BCF36F71-C09F-444D-A118-21E608F19408Q33856067-5A63AD76-5EA5-4FF5-8C7C-E495FF8AE930Q33866424-EB51AF55-B744-453E-9C3E-3CED3AD35F56Q33967624-B286A4B3-45A9-4895-B579-E944B8418904Q34005392-B54954E3-1F54-4784-BA5A-C2F592BE7F6AQ34069023-51B211D2-2596-4AF2-9594-3D57C524A261Q34172130-0323DD1D-2F14-464C-81C4-76629A1F7674Q34231216-FCCF7450-05A6-4469-ADE6-B3F82351DC27Q34350019-62D34DC4-4962-403C-8866-7FDC2407A193Q34431547-F9107CB3-2C31-47A7-98DB-0FE1C5ED3D63Q34452049-554A3C1F-6617-4B71-A5F6-4C03AD8CF174Q34647625-68B5DA09-4950-46CC-95D6-20060ECF5B77Q35868054-BBF97063-5DAA-4982-81E0-DA6644073D45Q36086635-5FB0F57E-8496-4A1A-8F67-FC724D23A542Q36181158-76BD4190-91C3-41B5-9A5F-10316E791FFDQ36284536-C9754613-A995-4828-B3B4-B28DA176F3E9Q36879345-B3625CDD-C689-4B9D-B9E0-8C8F74F6E8FAQ37127506-8C1CAA29-B4CD-47EF-8283-C5B003C203E7Q37249720-06038195-7B5F-43CC-BDC9-DABF0FEDF99EQ37991272-D646CC0B-640F-4228-AFD3-EB11B4774449Q38006997-8E145B59-1B17-4094-B00D-7AE1A6B2BF8CQ38212516-9372605B-5D46-4FA3-B73B-3B89AA0D3C34Q39548701-9F519A09-6896-477F-AC63-709B9617A6C8Q40835549-CD6A204D-01D6-49E8-8149-44D17EF85AFAQ41604739-5C96A009-273F-46F5-9476-8CAEB72527DDQ45568730-05294E28-BB28-4F86-B2ED-C830FD38295BQ45710545-6D74B516-D9A5-41C0-B4EE-F2A21B0119DAQ45751762-9515F30C-6628-4E06-9C98-71EA47F8F228
P2860
Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunization with DNA vaccines ...... erpes simplex virus-2 disease.
@en
Immunization with DNA vaccines ...... erpes simplex virus-2 disease.
@nl
type
label
Immunization with DNA vaccines ...... erpes simplex virus-2 disease.
@en
Immunization with DNA vaccines ...... erpes simplex virus-2 disease.
@nl
prefLabel
Immunization with DNA vaccines ...... erpes simplex virus-2 disease.
@en
Immunization with DNA vaccines ...... erpes simplex virus-2 disease.
@nl
P2093
P2860
P356
P1476
Immunization with DNA vaccines ...... erpes simplex virus-2 disease.
@en
P2093
P2860
P304
11414-11420
P356
10.1073/PNAS.93.21.11414
P407
P577
1996-10-01T00:00:00Z